IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression - Top-Institutions - MDSpire

IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression

  • By

  • Alexandre Pérez-González

  • Jacobo Alonso-Domínguez

  • Inés Martínez-Barros

  • Aida López-López

  • Laura Labajo-Leal

  • Antonio Ocampo

  • Eva Poveda

  • May 28, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    IIS Galicia Sur Health Research Institute
    IIS Galicia Sur Health Research Institute

    Santiago de Compostela, Galicia

    Key Differentiators

    • Infectious Disease

  • #2

    Álvaro-Cunqueiro Hospital
    Álvaro-Cunqueiro Hospital

    Vigo, Galicia

    Key Differentiators

    • Infectious Disease

  • #3

    HIV Prevention Trials Network
    HIV Prevention Trials Network

    Durham, North Carolina

    Key Differentiators

    • Infectious Disease

Original Source(s)

IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression

  • by Alexandre Pérez-González, Jacobo Alonso-Domínguez, Inés Martínez-Barros, Aida López-López, Laura Labajo-Leal, Antonio Ocampo, Eva Poveda

  • May 28, 2026

Related Content

Hantavirus Outbreak Revives COVID-Era False Health Claims — The Monitor

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Targeting VISTA for immunomodulation in sepsis: mechanisms and therapeutic potentials